Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 14.00
Bid: 13.50
Ask: 14.50
Change: -0.25 (-1.75%)
Spread: 1.00 (7.407%)
Open: 14.25
High: 14.00
Low: 13.75
Prev. Close: 14.25
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

New Venture Company

11 Feb 2005 07:00

Angle PLC11 February 2005 For Immediate Release 11 February 2005 ANGLE plc CUSTOMISER GROUP: NEW VENTURE COMPANY ANGLE plc, the venture management and consulting company specialising in thecommercialisation of technology, is pleased to announce the launch of its latestventure company, Customiser Group Ltd ('Customiser'). In accordance with ANGLE's Progeny(R) process for creating new ventures,Customiser has secured intellectual property utilising psychological profiling(more normally found in clinical psychology) and advanced pattern recognition.The approach has been developed and patented by a team of leading academicsacross a number of UK Universities. ANGLE expects to spend up to £500,000 inthis Progeny(R) venture. Global spend on the internet is now well in excess of $100bn per year andrevenues from internet advertising now exceed $10bn per year. The market fortailoring content to individual users is still in its infancy, but is alreadygenerating several hundred million dollars per annum in revenue and is widelypredicted to grow rapidly. Customiser's technology improves targeting of on-line advertising on internetportal sites, relevancy of search results and product recommendations withinretail sites. The Customiser solution produces substantially better resultsthan rivals which rely simply on data such as demographics and internet browsingbehaviour. It is expected that in the future, through Customiser's solution, internet userswill welcome personalised online adverts, search results and productrecommendations rather than wasting time with irrelevant information. Similarlyinternet advertisers and retailers will target personally meaningful adverts andproduct recommendations to receptive customers. Commenting on the collaboration with ANGLE, the technology development team'sAndrew Fraser, said: "We believe that internet personalisation will be worth several billion dollarsin the next few years and our collaboration with ANGLE will place us in anoutstanding position in this market." ANGLE's Chief Executive Andrew Newland said: "Customised on-line advertising and internet retailing are new but significantmarkets with enormous potential for growth. Customiser's solution offersincreased effectiveness in internet advertising, search results and productrecommendation placing us at the forefront of the rapidly emergingpersonalisation market." For further information ANGLE plc 01483 295830Andrew Newland, Chief ExecutiveDawson Buck, Deputy Chief Executive Buchanan Communications 020 7466 5000Richard Darby, Suzanne Brocks Notes to Editors Founded in 1994, ANGLE is an international venture management and consultingcompany focusing on the commercialisation of technology and the development oftechnology-based industry. ANGLE creates, develops and advises technologybusinesses on its own behalf and for its clients. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
10th Jan 20227:00 amRNSInsight into drug resistance in NSCLC
22nd Dec 20216:29 pmRNSIssue of Equity
1st Dec 20216:11 pmRNSIssue of Equity
1st Dec 20217:00 amRNSParsortix in RNA analysis of CTCs as tool in NSCLC
26th Nov 20215:33 pmRNSIssue of Equity
17th Nov 202110:32 amRNSIssue of Equity
15th Nov 20217:00 amRNSIssue of LTIP Options and Share Options
15th Nov 20217:00 amRNSAppointment of Chief Medical Officer
12th Nov 20215:51 pmRNSIssue of Equity
12th Nov 20217:00 amRNSParticipation at Jefferies healthcare conference
11th Nov 20217:00 amRNSParsortix system showcased at NCRI Festival
10th Nov 20215:40 pmRNSIssue of Equity
2nd Nov 20217:00 amRNSChange of Adviser
21st Oct 20215:25 pmRNSIssue of Equity
15th Oct 20215:45 pmRNSIssue of Equity
30th Sep 20214:02 pmRNSIssue of Equity
30th Sep 20217:00 amRNSInterim Results
27th Sep 20217:00 amRNSParsortix demonstrates ability to isolate CTCs
22nd Sep 20217:00 amRNSStudy shows use of Parsortix to assess PD-L1
20th Sep 20217:00 amRNSParsortix enables gene expression analysis in mPCa
7th Sep 20217:00 amRNSNotice of Interim Results and Webcast
24th Aug 20217:00 amRNSDirector/PDMR Shareholding
9th Aug 20217:00 amRNSStudy highlights superior performance of Parsortix
6th Aug 20211:17 pmRNSIssue of Equity
3rd Aug 20213:13 pmRNSIssue of Equity
28th Jul 20217:00 amRNSContract secured for bespoke assay development
9th Jul 20217:00 amRNSHarvesting CTCs from brain metastasis patients
7th Jul 20216:34 pmRNSDirector/PDMR Shareholding
2nd Jul 202110:45 amRNSIssue of Equity
30th Jun 20213:44 pmRNSResult of AGM
25th Jun 20217:00 amRNSResult of Accelerated Bookbuild
24th Jun 20216:28 pmRNSAccelerated bookbuild to raise up to £20m
18th Jun 202111:42 amRNSAnnual General Meeting update
18th Jun 20217:00 amRNSctDNA and CTCs have differences in EGFR mutations
4th Jun 20217:00 amRNSUpdate on submission for FDA clearance
1st Jun 20217:00 amRNSPotential to prevent breast cancer relapse
20th May 20217:00 amRNSParsortix demonstrates oesophageal cancer utility
19th May 20214:37 pmRNSExercise of options and total voting rights
11th May 20217:00 amRNSParsortix study uncovers targets in TNBC patients
30th Apr 202111:22 amRNSExercise of options and total voting rights
29th Apr 20217:00 amRNSPreliminary Results
26th Apr 20217:00 amRNSOvarian cancer study patient enrolment completed
19th Apr 20212:05 pmRNSSecond Price Monitoring Extn
19th Apr 20212:00 pmRNSPrice Monitoring Extension
19th Apr 202111:05 amRNSSecond Price Monitoring Extn
19th Apr 202111:00 amRNSPrice Monitoring Extension
16th Apr 20217:00 amRNSFirst large-scale pharma services contract secured
15th Apr 20214:10 pmRNSNotice of Preliminary Results and Webcast
12th Apr 20217:00 amRNSANGLE's Parsortix system showcased at AACR 2021
30th Mar 20217:00 amRNSGlobal launch of clinical services laboratories

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.